Search research articles
Contact Us
Filters
Showing results (121-130 of 132) with videos related to
Page
of 14
Sort By:
Molecular Oncology
|
September 16, 2025
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, et al.
Blood
|
April 9, 2017
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial
Jeffrey W Taub, Jason N Berman, Johann K Hitzler, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
January 9, 2025
ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
Jenna L Carter, Yongwei Su, Eman T Al-Antary, et al.
Nature Communications
|
November 18, 2017
An unexpected protein interaction promotes drug resistance in leukemia
Aaron Pitre, Yubin Ge, Wenwei Lin, et al.
Cancer
|
August 19, 2020
Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia
Seth E Karol, Todd M Cooper, Paul E Mead, et al.
Blood
|
March 31, 2021
Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
Xiaojia Niu, Katharina Rothe, Min Chen, et al.
Nature Reviews. Clinical Oncology
|
September 1, 2025
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia
Antonino Glaviano, Ellen Weisberg, Hiu Y Lam, et al.
Biochemical Pharmacology
|
February 15, 2026
Loss of cystathionine-β-synthase contributes to elevated OXPHOS, a vulnerability in ara-C-resistant myeloid Leukemia in Down syndrome
Jenna Thibodeau, Jianlei Zhao, Holly Edwards, et al.
Research Square
|
May 10, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis
Katie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Biochemical Pharmacology
|
December 11, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro
Katie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 132) with videos related to
Sort By:
Page
of 14
Molecular Oncology
|
September 16, 2025
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, et al.
Blood
|
April 9, 2017
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial
Jeffrey W Taub, Jason N Berman, Johann K Hitzler, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
January 9, 2025
ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
Jenna L Carter, Yongwei Su, Eman T Al-Antary, et al.
Nature Communications
|
November 18, 2017
An unexpected protein interaction promotes drug resistance in leukemia
Aaron Pitre, Yubin Ge, Wenwei Lin, et al.
Cancer
|
August 19, 2020
Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia
Seth E Karol, Todd M Cooper, Paul E Mead, et al.
Blood
|
March 31, 2021
Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
Xiaojia Niu, Katharina Rothe, Min Chen, et al.
Nature Reviews. Clinical Oncology
|
September 1, 2025
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia
Antonino Glaviano, Ellen Weisberg, Hiu Y Lam, et al.
Biochemical Pharmacology
|
February 15, 2026
Loss of cystathionine-β-synthase contributes to elevated OXPHOS, a vulnerability in ara-C-resistant myeloid Leukemia in Down syndrome
Jenna Thibodeau, Jianlei Zhao, Holly Edwards, et al.
Research Square
|
May 10, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis
Katie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Biochemical Pharmacology
|
December 11, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro
Katie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Page
of 14